Genmab — Juli 2024

[Solsen]

Epkinly $17/27/63 mln i hhv Q4/Q1/Q2 jf https://proinvestor.com/investornyt/1190236/genmabs-kraefthab-viser-fortsat-solide-vaekstrater - det tegner godt

[E_L]

either I am dyslexic or thiose journalists are.. i thought it was 36mn, not 63?

[E_L]

and i don't think they realise that this is the abbvie part, so total sales are approx double

[Solsen]

Iam not sure how they account the revenue. Genmab take 50% in US and Japan all other goes til Abbvie is my belive. But absolutely not sure.

[Solsen]

De $63 mln kan være 6 mdr jf Abbvies regnskab så tallene kan være $17/23/36 for de sidste 3 kvartaler. Genmab omtaler at de indregner US og Japan (record) og modtager 22-26% royalty for rw. Men der er noget der ikke passer her

[E_L]

That is corect. it was easy up to now; it was 50/50 as sales were practically all US. But with more sales in Europe it will not end up being AbbVie sales *2 anymore at some point

[Solsen]

Genmab says in annual report 2023 that they recorded $61 mln revenue of Epkinley.

[Solsen]

https://investors.abbvie.com/static-files/81a1993c-c366-44dc-89d7-106c21327573 p43. Abbvie in 2023: collaboration revenue $28 mln and International $3 mln.

[Solsen]

Revenue outside US and Japan in 2023: $3 mln. Revenue US and Japan $61 mln. Total 2023 for Epkinly: $64 mln (perhaps)

[Solsen]

https://investors.abbvie.com/static-files/c9936258-3a4c-48f0-968b-6d533ead6dee p7. If we take 3 month “revenue” data 14+22=36 then I belive real Epkinly revenue could be 31+32=63 (US+RW=Total) and the souce could right. My estimate is 45% of US revenue as collaboration revenu and Japan 8 mln out of the 22 mln recorded by Abbvie. If its true Genmab should record $38-40 mln in Q2 as Epkinly revenue. But hope we somewhere will get the revenue figures more easy

[E_L]

you have to start dialing a Danish phone number now if
you want Trial Information on PRO1184 https://www.clinicaltrials.gov/study/NCT05579366?tab=history&a=16&b=17#version-content-panel

[E_L]

AbbVie (ABBV) Q2 2024 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2024/07/25/abbvie-abbv-q2-2024-earnings-call-transcript/

[E_L]

" we continue to be pleased with the prescription trends for Epkinly in DLBCL. Commercialization is now underway for Epkinly's second indication, follicular lymphoma, in the U.S.

with European approval expected later this year."

[E_L]

"
In the area of hematologic oncology, we received accelerated approval in the U.S. for Epkinly as a monotherapy treatment for patients with relapsed/refractory follicular lymphoma after two or more lines of prior therapy. Epkinly is now the only T-cell-engaging bispecific approved in the U.S.

to treat both follicular lymphoma and diffuse large B-cell lymphoma. We're extremely excited to bring this new subcutaneous treatment option to patients suffering from follicular lymphoma.

[E_L]

We also recently received positive CHMP opinion with an approval decision in Europe expected later this year"

[E_L]

@Solsen medwatch corrected following your analysis
https://medwatch.dk/Medicinal___Biotek/article17305159.ece

[gentogen]

Det er vel fortsat forkert at hævde, at tallene er salgstal (?). Abbvie oplyser ikke salgstallene, men kun deres eget revenue

[gentogen]

I øvrigt antager jeg, at de 63 blot er halvårssummen af kvartalerne med 27 og de 36

[E_L]

correct

[JKY_VH]

Jep fra MW "(Korrektion: Tidligere opgjorte salgstal for andet kvartal på 63 mio. dollar var for første halvår)

Genmab kan se salget af kræftbehandlingen Epkinly gå yderligere frem i andet kvartal.

I andet kvartal nåede salget af Epkinly 36 mio. dollar, viser regnskabet fra den amerikanske medicinalkoncern Abbvie.

Dermed fortsætter fremgangen efter at salget i første kvartal nåede 27 mio. dollar og 17 mio. dollar i fjerde kvartal."